Form 4: Relmada Therapeutics Director Fabiana Fedeli Acquires and Forfeits Stock Options

Director Fabiana Fedeli acquired and simultaneously forfeited stock options in Relmada Therapeutics on May 24, 2024, related to the company's 2021 Equity Incentive Plan.

Summary

• On May 24, 2024, Fabiana Fedeli, a director of Relmada Therapeutics, acquired options for 20,976 shares of common stock at an exercise price of $2.48 per share.
• These options were granted under the terms of the December 15, 2023 option award, becoming available due to expirations, cancellations, forfeitures, and terminations of other outstanding awards under the company's 2021 Equity Incentive Plan.
• On the same day, Ms. Fedeli voluntarily forfeited these 20,976 options back to the issuer.
• The forfeited shares will be allocated to holders of similar awards who are not executive officers or directors of the Issuer.
• Following these transactions, Ms. Fedeli directly owns 52,498 stock options.

Sentiment

Score: 6

Explanation: The document reflects standard corporate governance procedures related to stock options. The acquisition and immediate forfeiture suggest a strategic decision related to equity distribution, which is neither overtly positive nor negative.

Positives

• The reallocation of forfeited options to non-executive employees could improve morale and align incentives.
• The forfeiture demonstrates a commitment to equitable distribution of equity incentives within the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• The Reporting Person became entitled to receive options for up to 20,976 additional shares of the Issuer's Common Stock on the same terms as the December Award.
• The Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer.

Industry Context

This announcement is typical of executive compensation disclosures and provides transparency into stock option grants and forfeitures, which are common practices in publicly traded companies, especially in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity incentive plans to attract and retain talent.
• The terms of Relmada's 2021 Equity Incentive Plan, including provisions for forfeitures and reallocations, are consistent with industry practices.

Stakeholder Impact

• Shareholders may view the reallocation of forfeited options as a positive step towards equitable compensation practices.
• Employees who receive the reallocated options may experience increased motivation and alignment with company goals.

Key Dates

Keywords

stock options, Relmada Therapeutics, Fabiana Fedeli, equity incentive plan, forfeiture, director, RLMD